# aTyr Pharma (ATYR) — News

ATYR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/atyr/news

## Recent headlines

- [Trading released/resumed: (ATIU) Reason not available](https://www.ainvest.com/news/trading-released-resumed-atiu-reason-2610) — AInvest Wire, Oct 13, 2026
  Trading in the security identified by the symbol ATIU has resumed following a prior halt, though the specific reason for the halt remains unavailable at this time. According to standard trading halt protocols, such occurrences may be triggered by pending news releases, regulatory concerns , or…
- [Trading halted: (ATIU) Due to limit-up limit-down trading pause](https://www.ainvest.com/news/trading-halted-atiu-due-limit-limit-trading-pause-2610) — AInvest Wire, Oct 13, 2026
- [Atry Pharma provides update on timing of regulatory response for planned phase 3 study of efzofitimod in pulmonary sarcoidosis](https://www.ainvest.com/news/atry-pharma-update-timing-regulatory-response-planned-phase-3-study-efzofitimod-pulmonary-sarcoidosis-2609) — AInvest Wire, Sep 1, 2026
  aTyr Pharma, Inc. (Nasdaq: ATYR) has outlined its next steps for the development of efzofitimod in pulmonary sarcoidosis following a Type C meeting with the U.S. Food and Drug Administration (FDA). The company plans to submit an investigational new drug (IND) application for a new Phase 3 study in…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).